Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTx’s unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinson’s and other CNS diseases.

Biotechnology

Education

Lucy Therapeutics

Amy Ripka

Allen Hopper

Yipeng Du

Vera Procaccia

Minevere Sinani

Robin Grammer

Jessica Garrant

Bryan Keaney

The Leadership Team at Lucy Therapeutics drives the strategic vision and operational execution of the company’s mission to revolutionize drug discovery through early intervention in disease pathogenesis. Composed of key executives including the CEO and CFO, the team oversees business development, financial strategy, and the advancement of innovative therapies targeting mitochondrial function in neurodegenerative diseases, ensuring alignment with the company's unique approach to disease modification and proof of concept initiatives.

Leadership Team

Scientific Advisors

Research and Development Team

Leadership Team

About

Team members

Other teams at Lucy Therapeutics

Scientific Advisors

Research and Development Team